angiex.com
Get leads like Angiex — and thousands more
Build targeted lists by tech stack, traffic, and more
The Stealth Biotech Weaponizing Cancer's Own Biology
A 16-person team is building Nuclear-Delivered Antibody-Drug Conjugates that bypass traditional cancer defenses.
While most biotechs chase incremental improvements, Angiex is exploiting a fundamental blind spot in cancer biology. Their approach isn't just about delivering drugs—it's about delivering them directly to the command center of the cell, where tumors can't escape.
"They're not just building another ADC—they're building a Trojan horse that enters the nucleus itself."
The Nuclear Delivery Revolution
Traditional antibody-drug conjugates (ADCs) work by binding to cancer cell surfaces and releasing toxins. Angiex's Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) do something radically different: they deliver cytotoxic payloads directly into the cell nucleus. This bypasses efflux pumps and other resistance mechanisms that have plagued conventional ADCs. Think of it as the difference between attacking a castle's outer walls versus infiltrating its keep.
The Lean Scientific Machine
With just 16 employees and $2.5M in revenue, Angiex operates with surgical precision. This isn't a sprawling pharmaceutical giant—it's a focused biotech weapon. The team includes specialized scientists like Aaron Mallek (Senior Scientist, Chemistry) and CMC Project Manager Soyeong Park, suggesting deep expertise in manufacturing and process development. Their small size isn't a limitation; it's a strategic advantage, allowing them to move faster than larger competitors.
The traffic data reveals something telling: 42% direct traffic and 33% organic search. This isn't a company chasing broad keywords or mass-market attention. Their audience is highly specific—oncologists, researchers, and investors who know exactly what they're looking for. The top keyword 'oncologist jason dukas' confirms this: they're attracting medical professionals by name, not through generic biotech buzzwords.
- Nuclear-delivered mechanism bypasses traditional resistance pathways
- Lean 16-person team with deep manufacturing and clinical expertise
- $2.5M revenue from focused biotech operations
- 42% direct traffic indicates strong brand recognition in niche
- World ADC poster suggests active presence in industry conferences
The Quiet Giant in Nuclear Delivery
While competitors chase surface-level targets, Angiex is going nuclear—literally. This is a company to watch in the ADC space, especially for investors who understand that the biggest breakthroughs often come from the smallest, most focused teams.
What tech stack does Angiex use?
How much traffic does Angiex get?
Traffic & Engagement
Traffic Sources
Where is Angiex's audience located?
What keywords does Angiex rank for?
1 keywordsHow is Angiex's SEO?
Open Graph Image
https://angiex.com/ASSETS/IMG/news/_1200x630_crop_center-center_none/news-default.png
Meta Tags
Home - Angiex
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality
H1 Tags
What is Angiex's revenue?
Who works at Angiex?
Loading leads...
What do customers think of Angiex?
No Trustpilot reviews available for this company.
Frequently Asked Questions about Angiex
What is Angiex's Revenue?
What does Angiex do?
How fast is Angiex growing?
What technologies does Angiex use?
Who are Angiex's competitors?
Export Data
Unlock all exports
Download CSVs, JSONs & full reports
How to contact Angiex?
Contact Information
Export angiex.com Data
Download the complete tech stack, analytics, leads, and company data for angiex.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.
Raw JSON Data
Click "Show" to view the raw API response data
About angiex.com
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality
Company Overview
angiex.com Social Media
Contact angiex.com
Email Addresses
Phone Numbers
Technology Stack
angiex.com uses 5 technologies across their website including unpkg, Lazy Loading, Twitter Cards, PWA, and more.
CDN
unpkg
Performance
Lazy Loading
Web Standards
Twitter Cards, PWA
JavaScript Libraries
Lottie
Traffic & Audience
angiex.com receives approximately 163 monthly visitors and ranks #7,878,303 globally. The website has a bounce rate of 40% with visitors viewing an average of 1.1 pages per visit. Users spend an average of 0:00 on the site.
The majority of angiex.com's traffic comes from .
Frequently Asked Questions
What is angiex.com?
What technologies does angiex.com use?
How do I contact angiex.com?
What are angiex.com's social media accounts?
Is angiex.com hiring?
How popular is angiex.com?
Related Searches
This page provides publicly available information about angiex.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit angiex.com directly at https://angiex.com.